Intercept Pharma (ICPT) Halted Ahead of FDA AdCom for OCA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Needham & Company Reiterates Buy on Intercept Pharma (ICPT) Following Positive FDA Panel Vote on Obeticholic Acid
April 8, 2016 6:53 AM EDTNeedham & Company reiterated a Buy rating and $350.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following an FDA panel vote in favor of Obeticholic Acid approval.
Analyst Alan Carr commented, "The FDA Gastrointestinal Drugs Advisory Committee voted yesterday 17-0 in favor of Obeticholic Acid... More
